A pilot program that introduces one-day inspectional assessments, a streamlined oversight tool designed to expand the agency’s surveillance reach while preserving regulatory rigor, has been launched by the US Food and Drug Administration (FDA), according to officials.
The initiative, which began in April, is part of a broader FDA